OC.05.3 ROSIGLITAZONE REDUCES THE IN VITRO AND IN VIVO ONCOGENIC POTENTIAL OF HCC CELLS THROUGH A PPARGAMMA-INDEPENDENT NON-GENOMIC INHIBITION OF RUVBL-1

Authors :: Andrea Galli
Tommaso Mello
Elisabetta Ceni
Stefano Milani
Simone Polvani
Mirko Tarocchi
F. Buccoliero
Source :: Digestive and Liver Disease. 44:S66-S67
Publication Year :: 2012
Publisher :: Elsevier BV, 2012.

Subjects :: Hepatology
business.industry
In vivo
Gastroenterology
Cancer research
Medicine
business
Rosiglitazone
In vitro
medicine.drug

Full Text Access

Tools